<DOC>
	<DOCNO>NCT01416558</DOCNO>
	<brief_summary>Nab-paclitaxel demonstrate active agent breast cancer probably less toxic alternative solvent base taxanes . It indicate metastatic breast cancer failure anthracyclines . However , patient receive anthracyclines well taxanes part ( neo- ) adjuvant therapy . There currently standard treatment patient early relapse ( &lt; 12 month ) taxane contain ( neo- ) adjuvant therapy . Nab-paclitaxel , novel nano-particle encapsulate paclitaxel expect limited cross-resistant solvent-based taxanes might therefore indicated setting .</brief_summary>
	<brief_title>Nab-paclitaxel Metastatic Breast Cancer Patients Failing Solvent Based Taxane ( Tiffany )</brief_title>
	<detailed_description>Primary Objective : To determine overall response rate ( ORR ) exclude 20 % low . Secondary Objectives : 1 . To determine compliance toxicity therapy . 2 . To determine clinical benefit rate ( CBR ) patient measurable disease . 3 . To determine duration response . 4 . To determine progression-free survival ( PFS ) . 5 . To determine overall survival . 6 . To assess biomarkers , e.g . SPARC expression tissue primary metastatic tumor .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Written inform consent study procedure accord local regulatory requirement prior begin specific protocol procedure . Complete baseline documentation must submit via webbased data collection system MedCODES GBG Forschungs GmbH . Diagnosis locally advance metastatic hormonesensitive insensitive , HER2negative positive breast cancer . Relapse within ≤ 12 month complete ( last day last cycle ) ( neo ) adjuvant chemotherapy . Documented relapse either measurable nonmeasurable lesion accord modify RECIST criterion . Previous neoadjuvant adjuvant treatment solvent base taxane ( paclitaxel docetaxel ) irrespective dose duration . Prior endocrine treatment metastatic / advance disease allow . Complete radiological clinical tumor assessment within 4 week prior registration perform clinically indicate . Age ≥ 18 year . ECOG Performance Status ≤ 2 ( irrespective restriction due breast cancer ) . Laboratory requirement : Absolute neutrophil count ( ANC ) &gt; = 1.5 x 109/L. , Platelets &gt; = 100 x 109/L. , Hemoglobin &gt; = 9 g/dL ( &gt; = 5.6 mmol/L ) . , Prothrombin time ( PT ) international normalize ratio ( INR ) &lt; = 1.2x ULN ( upper normal limit ) , Partial thromboplastin time ( PTT ) &lt; = 1.2x ULN , Total bilirubin &lt; 1.5x ULN , ASAT ( SGOT ) ALAT ( SGPT ) &lt; = 2.5x ULN ( concomitant elevation serum bilirubin ASAT/ALAT 1.0x ULN permit ) , Creatinine clearance &gt; = 50 mL/min ) , Urine Protein Creatinine Ratio ( UPC ) &lt; 1 ( UPC &gt; = 1 , 24hour urine protein must &lt; 1 g ) . Normal cardiac function confirm ECG . A female either : 1 ) Nonchildbearing potential , i.e . physiologically incapable become pregnant history hysterectomy , bilateral oophorectomy ( ovariectomy ) , bilateral tubal ligation postmenopausal status . 2 ) Childbearing potential negative pregnancy test ( urine serum ) within 2 week prior registration , preferably close first dose possible , agree use adequate contraception . Acceptable contraceptive method , use consistently accordance product label instruction physician , follow : An intrauterine device document failure rate le 1 % per year , Vasectomised partner sterile prior female subject 's entry sole sexual partner female , Complete abstinence sexual intercourse 14 day exposure investigational product , dose period , least 21 day last dose investigational product , Doublebarrier contraception ( condom spermicidal jelly , foam suppository , film ; diaphragm spermicide ; male condom diaphragm spermicide ) . Female subject lactate discontinue nursing prior first dose study drug refrain nursing throughout treatment period 14 day follow last dose study drug . Known suspected hypersensitivity reaction investigational compound incorporated substance . ( Neo ) adjuvant therapy contain solvent base taxane . ( Neo ) adjuvant therapy nabpaclitaxel . Concurrent hormonal therapy cancer . Life expectancy le 3 month . Preexisting peripheral neuropathy &gt; grade 2 ( per CTCAE ) . Preexisting grade 3 4 diarrhea . Presence uncontrolled infection . Any serious and/or unstable preexist medical , psychiatric , condition could interfere subject 's safety , provision inform consent , compliance study procedure . Concurrent specific systemic antitumor treatment treatment experimental compound study treatment .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>German Breast Group</keyword>
	<keyword>GBG Forschungs GmbH</keyword>
	<keyword>GBG</keyword>
	<keyword>GBG 65</keyword>
	<keyword>Tiffany</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>Metastatic Breast Cancer</keyword>
	<keyword>Nab-Paclitaxel</keyword>
	<keyword>Abraxane</keyword>
	<keyword>Taxane Failure</keyword>
</DOC>